It is expected to change the patient's compliance and will help them continue with the correct doses with ease of drinking water and getting desired outcomes.
The product is backed by required scientific proof and comparative bioequivalence studies and is approved by Central Drugs Standard Control Organisation (CDSCO).
The company is further looking to introduce Capebel 1 gm DT in various international markets through its partners and clients.
Shilpa Medicare is a global brand in manufacturing and supplying of affordable API and formulation globally in different regulated markets.
The company's reported a consolidated net loss of Rs 18.66 crore as against a net profit of Rs 19.96 crore in Q2 FY23 over Q2 FY22. Net sales declined 11% YoY to Rs 262.91 crore in the quarter ended 30 September 2022.
